Clinical trials
-
Exercise testing in DMD -
Platelet Function Testing Substudy - Investigator
- Larisa H Cavallari
-
Metastatic Ewing s Trial Testing Schedule Enhancement to Improve Outcomes This single arm study is designed to demonstrate the feasibility of a radically different approach for an exceptionally high-risk subset of MES with widely metastatic disease (WMES). We incorporate the use of evolutionary principles that apply to…
- Investigator
- Joanne Lagmay
- Ages
- 1 Year - N/A
- Sexes
- All
-
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a polyadenosine…
- Investigator
- Kaitlin M Nicholson
- Ages
- 18 Years - N/A
- Sexes
- All
-
Testing the Addition of Gemcitabine to Usual Treatment (BCG Alone) in People With Recurrent HG NMIBC This phase III trial compares the effect of adding gemcitabine to intravesical Bacillus Calmette Guerin (BCG) versus intravesical BCG alone in patients with non-muscle invasive bladder cancer that has come back after a period of improvement…
- Investigators
- Paul L Crispen, Padraic O'Malley
- Ages
- 18 Years - N/A
- Sexes
- All
-
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment; Higher Risk MDS w/IDH2 This phase II MyeloMATCH treatment trial compares the usual treatment of cedazuridine-decitabine (ASTX727) to the combination treatment of ASTX727 and enasidenib in treating patients with higher-risk, IDH2-mutated myelodysplastic syndrome (MDS).…
- Investigator
- Dina Khalaf
- Ages
- 18 Years - N/A
- Sexes
- All
-
TOPMEDs The objectives of this study are to (1) test the feasibility of the clinical implementation of preemptive pharmacogenetic (PGx) testing in the emergency department (ED) and (2) determine if PGx testing (with appropriate decision support) decreases…
- Investigator
- Michael Marchick
- Ages
- 40 Years - N/A
- Sexes
- All
-
PINPOINT: Aim 3 Our overarching goal is to adapt and test the PINPOINT intervention -PatIent Navigation for the Prevention of CervIcal CaNcer inTervention. We will test the PINPOINT intervention among patients with high-risk profiles for cervical cancer who do not…
- Ages
- 25 Years - N/A
- Sexes
- Female
-
A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment o This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back after…
- Investigators
- William Slayton, Brian Stover
- Ages
- N/A - 22 Years
- Sexes
- All
-
TAPUR: Testing FDA Approved Drugs That Target Specific Abnormal Tumor Genes in Pts w/Advanced Cancer The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. Note: Due to…
- Investigator
- Thomas J George
- Ages
- 12 Years - N/A
- Sexes
- All